Gastric Cancer Drugs Market By Route Of Administration, Distribution Channel And Geography - Forecast And Analysis 2023-2027

Gastric Cancer Drugs Market Forecast 2023-2027

The Global Gastric Cancer Drugs Market size is estimated to grow by USD 12.76 billion at a CAGR of 14.85% between 2022 and 2027. Increasing awareness campaigns for gastric cancer is driving the market growth. For example, The Life Raft Group is a non-profit organization focused on informing, educating healthcare professionals, and supporting the conduct of innovative research to treat gastric cancer.

The GIST Cancer Research Foundation is another organization actively involved in raising awareness of the indication for gastric cancer therapy in the US. The organization is focused on providing patients and physicians with the necessary information about indications and support for patients and their families with gastric cancer. As a result, an increase in the number of awareness campaigns leads to an increase in the diagnosis of the disease in its early stages, leading to more patients receiving prompt treatment. This will drive the demand for gastric cancer drugs and drive market growth during the forecast period. This report also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the size of the Gastric Cancer Drugs Market During the Forecast Period?

To learn more about this report, Request Free Sample

The market is witnessing a surge in demand driven by the rising prevalence of gastric carcinoma cases and related conditions like gastric adenocarcinoma and gastrointestinal stromal tumors. Pharmaceutical giants are actively developing and introducing advanced treatments, such as Trastuzumab deruxtecan and Programmed Cell Death Protein 1 (PD-1) inhibitors like Keytruda, Herceptin, and Cyramza, aiming to improve patient outcomes and expand treatment options for patients worldwide.

Market Segmentation

Technavio has segmented the market into Route Of Administration, Distribution Channel, and Geography.  Herzuma, among other medications, plays a crucial role in combating gastric cancer, particularly for patients with a family history of the disease. These drugs are administered through different routes to target the affected areas, primarily the stomach lining, where cancerous cells manifest. Patients often experience symptoms such as nausea, fatigue, bloating, stomach pain, vomiting, and weight loss, necessitating prompt and targeted drug delivery to alleviate discomfort and combat the disease. Biomarkers are also utilized to identify specific treatment pathways tailored to individual patient needs, ensuring optimal therapeutic outcomes. Overall, the route of administration segment encompasses various approaches to deliver medications effectively, addressing the diverse symptoms while optimizing treatment efficacy and patient outcomes.

By Route Of Administration 

Injectable

The market share growth by the injectable segment will be significant during the forecast period. An injection is a method of delivering medication into the bloodstream using a needle under the skin, which is inserted through the skin into the body (muscle or nerve). Most of the drugs being developed in the later stages of the gastric cancer drug system are biologics. The injectable route remains the preferred route for biologics, as the oral route often inactivates the drug.

Get a glance at the market contribution of various segments View a PDF Sample

The injectable segment was valued at USD 6.32 billion in 2017. Nivolumab is an injectable medication provided by Bristol Myers Squibb Company. These drugs are expected to add significant value to the growth of the market due to their high efficiency and greater demand. The popularity of these drugs in the various indications of gastric cancer therapy is expected to attract a large number of patients to seek treatment with these drugs. Hence, the introduction of new injectable gastric cancer drugs will drive the growth of the market during the forecast period. 

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The high incidence of gastric cancer in the region and the availability of stomach cancer treatment are the key factors contributing to the growth of the regional market. The growing aging population is another factor contributing to the growth of the market in the region, as stomach cancer usually occurs in people over 50 years old. In addition, the availability of advanced healthcare infrastructure and the presence of leading pharmaceutical companies in North America are also contributing to the growth of the market. The major players are investing in research and development (R&D) to introduce effective drugs in the market, which is expected to drive the growth of the market during the forecast period. 

Buy Now Full Report and Discover More

Market Dynamics and Customer Landscape

The market addresses the pressing need for effective treatments against various gastric carcinoma cases, including Gastric Adenocarcinoma and Gastrointestinal Stromal Tumor. Innovative medications such as Trastuzumab deruxtecan, Keytruda, and Cyramza offer hope for patients by targeting specific cancer types and pathways. With advancements like Programmed Cell Death Protein 1 inhibitors and biosimilars Ogivri and Herzuma, treatment options continue to expand. Early detection through family history assessment and biomarkers is crucial, as symptoms like nausea, fatigue, and stomach pain can indicate underlying issues. This market underscores the ongoing efforts to combat gastric cancer and improve patient outcomes globally. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

The increasing prevalence of gastric cancer is the key factor driving the growth of the market. One of the key reasons for the increase in the rate of incidence is due to changes in lifestyle and eating habits. The consumption of processed and fast foods, high in fat and sugar, has become very common in recent years, leading to conditions such as obesity, which has been linked to chronic digestive disorders, including gastric cancer. In addition, a sedentary lifestyle without any physical activity or exercise is becoming increasingly popular, as many people have busy work schedules that leave them no time to exercise.

Moreover, the increase in the incidence of gastrointestinal cancer has a significant impact on patients and their families. Patients may experience chronic pain, loss of appetite, and reduced quality of life. Hence, the above-mentioned factors are expected to increase the demand for gastric cancer drugs globally, which is expected to drive the growth of the global market during the forecast period. 

Significant Market Trends

An increase in number of drug approvals and drug launches is a primary trend in the market. Over the past few years, there has been a significant increase in the number of regulatory agencies approving drugs for stomach cancer treatment. The US FDA has worked closely with pharmaceutical companies to streamline the approval process for these drugs, resulting in faster turnaround times from submission to approval.

Moreover, market players have launched new gastric cancer products. For instance, in March 2022, Samsung Biologics Co. Ltd. announced the launch of ONTRUZANT (trastuzumab-dttb) in the US for the treatment of early-stage and metastatic HER2-overexpressing breast cancer as well as metastatic gastric cancer. Hence, the increase in the number of drugs approved and launched is expected to drive the growth of the target market during the forecast period.

Major Market Challenges

The presence of alternative treatment methods is the challenge that affects the growth of the market. Surgery for stomach cancer, also known as gastric cancer, aims to completely remove the disease. Surgery may be the first line of treatment for small stomach malignancies. If stomach cancer progresses to the lymph nodes or invades deeper into the stomach wall, other treatments may be tried first.

Furthermore, another stomach cancer treatment includes radiation therapy. High-energy beams are used in radiation therapy to kill cancer cells. The beams can come from protons, X-rays, or other sources. If the cancer has spread or cannot be operated on, radiation therapy may be used to treat the symptoms of stomach cancer. Therefore, the presence of different treatments, such as surgery and radiation therapy, will impede the demand for market during the forecast period.

Buy Now Full Report and Discover More

Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Customer Landscape

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Abbott Laboratories: The company offers a gastric-cancer drug called Priunta 440mg Injection.

• AbbVie Inc.
• AROG Pharmaceuticals INC.
• AstraZeneca Plc
• Bayer AG, Biocon Ltd.
• Blueprint Medicines Corp.
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Celltrion Co. Ltd.
• Dr Reddys Laboratories Ltd.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Merck KGaA
• Novartis AG
• Samsung Biologics Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Zydus Lifesciences Ltd.
• Otsuka Holdings Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Analyst Overview

The market is witnessing significant advancements in the treatment landscape, driven by the rising incidence of gastric carcinoma cases and related conditions such as Gastric Adenocarcinoma and Gastrointestinal Stromal Tumor. Pharmaceutical giants like Pfizer are pioneering the development of innovative therapies such as Trastuzumab deruxtecan and Programmed Cell Death Protein 1 inhibitors like Keytruda and Opdivo. These medications offer promising outcomes, especially for patients with specific genetic markers or those resistant to conventional treatments like Herceptin and Cyramza. Additionally, the market is witnessing the emergence of biosimilars from companies like Biocon/Mylan and Celltrion/Teva, including Ogivri and Herzuma, providing more affordable alternatives. With a focus on biomarkers and personalized medicine, the industry aims to improve outcomes and quality of life for patients experiencing symptoms like nausea, fatigue, stomach pain, bloating, vomiting, and weight loss.

The market is witnessing remarkable advancements in treatment options, particularly for complex conditions like Gastric Neuroendocrine Tumors and Gastrointestinal Stromal Tumors (GIST). Pharmaceutical innovations such as PD-1 inhibitors like Avelumab and Trazimera are revolutionizing immunotherapy, providing new hope for patients with advanced disease stages. Additionally, HER2 antagonists and VEGFR antagonists are proving effective in targeting specific molecular pathways, while chemotherapy agents like Lonsurf, Fluorouracil, and Capecitabine remain essential components of treatment regimens. Specialty and hospital pharmacies play crucial roles in ensuring access to these medications, including novel therapies like Enhertu and Oncoral, catering to diverse patient needs, including those with a family history of gastric cancer or related conditions like Gastroesophageal reflux disease and Gastroesophageal junction cancer.

The market addresses various risk factors and treatment modalities associated with gastric cancer, including Gastroesophageal reflux disease (GERD) and smoking, both of which are significant contributors to the development of the disease. Advances in genetic modification techniques have led to the development of targeted therapies that aim to address specific molecular abnormalities driving gastric cancer progression. Oral drugs play a crucial role in treatment regimens, offering convenience and efficacy in managing the condition. However, protecting the stomach lining from adverse effects remains a priority in drug development. 

Segment Overview

The market research and growth report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Route Of Administration Outlook 
  • Injectable
  • Oral

• Distribution Channel Outlook 
  • Offline
  • Online

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Argentina
    • Austrelia
    • Brazil

Market Scope
Report Coverage	Details
Page number	160
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 14.85%
Market growth 2023-2027	USD 12,764.91 million
Market structure	Fragmented
YoY growth 2022-2023(%)	13.81
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 40%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, AbbVie Inc., AROG Pharmaceuticals INC., AstraZeneca Plc, Bayer AG, Biocon Ltd., Blueprint Medicines Corp., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Co. Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Merck KGaA, Novartis AG, Samsung Biologics Co. Ltd., Takeda Pharmaceutical Co. Ltd., Zydus Lifesciences Ltd., and Otsuka Holdings Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2023 and 2027
• Precise estimation of the market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Market growth analysis across North America, Europe, Asia, and the Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Market forecasting of factors that will challenge the growth of key market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch